Preservation of fertility despite subnormal gonadotropin and testosterone levels after cessation of pulsatile gonadotropin-releasing hormone therapy in a man with Kallmann’s syndrome**Supported by grants P50-HD-1262 and K0800890-01 from the National Institutes of Health, Bethesda, Maryland; research funds from the Department of Veterans Affairs; and the Clinical Research Center of the University of Washington, Seattle, Washington, supported by National Institutes of Health grant RR-37.
1994 ◽
Vol 61
(2)
◽
pp. 392-394
◽
1986 ◽
Vol 46
(4)
◽
pp. 578-585
◽
1993 ◽
Vol 60
(3)
◽
pp. 418-422
◽
1996 ◽
Vol 65
(3)
◽
pp. 539-544
◽
1975 ◽
Vol 26
(7)
◽
pp. 655-659
◽
1991 ◽
Vol 56
(3)
◽
pp. 427-433
◽
1979 ◽
Vol 32
(2)
◽
pp. 177-182
◽
1987 ◽
Vol 48
(3)
◽
pp. 423-427
◽
1998 ◽
Vol 81
(6)
◽
pp. 805-807
◽